Cheryl London A DVM, PhD


Cheryl London A DVM, PhD
ProfessorCollege of Veterinary Medlondon.20@osu.edu
0454 Veterinary Medicine Acad Bldg 1900 Coffey Road Columbus Ohio 43210
Phone:614-292-9554Fax: (614) 292-7599
  • Translational Therapeutics

Research Description

Dr. London's research includes the use of spontaneous tumors in dogs and cats as models for human cancer, investigation of kinase dysfunction in animal tumors, and mouse models of Kit dysregulation

Current Publications

  • London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR, McCauley D, Kauffman M, Shacham SPreclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.PLoS One 9 e87585 1/1/2014
  • Fenger JM, Bear MD, Volinia S, Lin TY, Harrington BK, London CA, Kisseberth WCOverexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis.BMC Cancer 14 84 1/1/2014
  • Karlsson EK, Sigurdsson S, Ivansson E, Thomas R, Elvers I, Wright J, Howald C, Tonomura N, Perloski M, Swofford R, Biagi T, Fryc S, Anderson N, Courtay-Cahen C, Youell L, Ricketts SL, Mandlebaum S, Starkey MP, Modiano JF, Breen M, Lindblad-Toh K, Rivera P, von Euler H, Kisseberth WC, London CA, Lander ES, Couto G, Comstock KGenome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B.Genome Biol in press R132 12/12/2013
  • Balkhi MY, Balkhi MY, Iwenofu OH, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CAmiR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.Sci Signal 6 ra63 7/30/2013
  • Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJDual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.Clin Cancer Res 19 2984-94 6/1/2013
  • McCleese JK, Bear MD, Kulp SK, Mazcko C, Khanna C, London CAMet interacts with EGFR and Ron in canine osteosarcoma.Vet Comp Oncol 11 124-39 6/1/2013
  • Martin CK, Dirksen WP, Carlton MM, Lanigan LG, Pillai SP, Werbeck JL, Simmons JK, Hildreth BE 3rd, London CA, Toribio RE, Rosol TJCombined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.Vet Comp Oncol in press 5/8/2013
  • Rutteman GR, Erich SA, Mol JA, Spee B, Grinwis GC, Fleckenstein L, London CA, Efferth TSafety and efficacy field study of artesunate for dogs with non-resectable tumours.Anticancer Res 33 1819-27 5/1/2013
  • Nguyen SM, Thamm DH, Vail DM, London CAResponse evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.Vet Comp Oncol in press 3/28/2013
  • London CAKinase dysfunction and kinase inhibitors.Vet Dermatol 24 181-7.e39-40 2/1/2013
  • Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CAEvaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.BMC Vet Res 9 190 1/1/2013
  • London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, Ettinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, Ladue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, Henry C, Gillings SPreliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.Vet Comp Oncol 10 194-205 9/1/2012
  • Vail DM, Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, Kurzman ISafety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.Vet Comp Oncol 10 174-83 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu